Mimedx Group Inc MDXG

$4.70 +0.02 (0.32%)

Valuation

Market cap
683,614,000
Revenue TTM
$418,630,000
Net income TTM
$48,580,000
PE ratio
25.42
Forward PE
—
Profit margin
11.60%
Debt to equity
0.01

Trading

Volume
714,233
Avg volume
1,092,272
Day's range
$4.71 – $4.88
Shares out
145,760,000
Stochastic %K
57%
Beta
1.18
Analysts
Strong Sell
Price target
$7.40

Price

Company profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors....

Show more

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Industry
Biotechnology
Sector
Healthcare
Phone
770 651 9100
Website
https://www.mimedx.com
Address
1775 West Oak Commons Court, NE, Marietta, United States

Latest news

Stocktwits

WarrenDouglasTrader Oct 14, 8:19 PM
$MDXG Earnings in 2 weeks, seems earlier than usual. Capper has been silent since last ER. Makes me very worried.
0 replies
StatenIsland Oct 14, 7:57 PM
$MDXG QQQ is down 3% and we're up is very telling.
1 replies
StatenIsland Oct 12, 7:25 PM
$MDXG orgo is going down the tube
3 replies
77HighStreet Oct 10, 12:34 PM
$MDXG Huge drop in short interest – down 1,397,804 shares…so, a reversal from two weeks ago.
1 replies
WarrenDouglasTrader Oct 8, 8:18 PM
$MDXG Is this company still alive? Total silence since last ER. Thanks Joe for keeping us up to speed.
1 replies
jmdaddy Oct 6, 5:36 PM
$MDXG I know everyone here knows this already...but it is something. Approved 9-30-2025
2 replies
WarrenDouglasTrader Oct 2, 2:26 PM
$MDXG Silence since last ER. Not good
0 replies
Stefonne Sep 30, 10:13 PM
$MDXG https://x.com/KanekoaTheGreat/status/2105375659401035868 Link, even Musk commented.
0 replies